BRPI0510167A - método para tratar, prevenir ou controlar hipertensão pulmonar - Google Patents

método para tratar, prevenir ou controlar hipertensão pulmonar

Info

Publication number
BRPI0510167A
BRPI0510167A BRPI0510167-0A BRPI0510167A BRPI0510167A BR PI0510167 A BRPI0510167 A BR PI0510167A BR PI0510167 A BRPI0510167 A BR PI0510167A BR PI0510167 A BRPI0510167 A BR PI0510167A
Authority
BR
Brazil
Prior art keywords
pulmonary hypertension
methods
treat
prevent
treating
Prior art date
Application number
BRPI0510167-0A
Other languages
English (en)
Inventor
Jerome B Zeldis
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BRPI0510167A publication Critical patent/BRPI0510167A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

MéTODO PARA TRATAR, PREVENIR OU CONTROLAR HIPERTENSãO PULMONAR. Divulga-se métodos de tratar, prevenir e controlar hipertensão pulmonar. Métodos específicos compreendem a administração de talidomida, ou um sal, solvato (por exemplo, hidrato), estereoisómero, clatrato, ou pró-droga farmacêuticamente aceitável do mesmo, sozinho ou em combinação com um segundo agente ativo, cirurgia e/ou transplante de pulmão. Segundos agentes ativos específicos são capazes de reduzir pressão arterial pulmonar. Divulga-se também composições farmacêuticas, formas de dosagem unitária simples, e kits vantajosos pra uso em métodos da invenção.
BRPI0510167-0A 2004-04-23 2005-04-21 método para tratar, prevenir ou controlar hipertensão pulmonar BRPI0510167A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56516904P 2004-04-23 2004-04-23
PCT/US2005/013596 WO2005102333A1 (en) 2004-04-23 2005-04-21 Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension

Publications (1)

Publication Number Publication Date
BRPI0510167A true BRPI0510167A (pt) 2007-10-02

Family

ID=35196727

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510167-0A BRPI0510167A (pt) 2004-04-23 2005-04-21 método para tratar, prevenir ou controlar hipertensão pulmonar

Country Status (12)

Country Link
US (1) US20050239719A1 (pt)
EP (1) EP1755599A4 (pt)
JP (1) JP2007533759A (pt)
KR (1) KR20070004123A (pt)
CN (1) CN1968696A (pt)
AU (1) AU2005234782A1 (pt)
BR (1) BRPI0510167A (pt)
CA (1) CA2563748A1 (pt)
IL (1) IL178785A0 (pt)
MX (1) MXPA06012277A (pt)
WO (1) WO2005102333A1 (pt)
ZA (1) ZA200609227B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
DK1615632T3 (da) * 2003-04-17 2007-04-10 Jallal Messadek Flydende orale formularer for kontrolleret udskillelse af betain
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2007106494A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
CA2674367A1 (en) * 2007-01-03 2008-07-17 Glenn V. Cornett Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
US9314229B2 (en) 2013-03-13 2016-04-19 Medtronic Vascular, Inc. Suturing device and method for sealing an opening in a blood vessel or other biological structure
US9271708B2 (en) 2013-03-13 2016-03-01 Medtronic Vascular, Inc. Suturing device and method for sealing an opening in a blood vessel or other biological structure
US10722558B2 (en) 2016-07-15 2020-07-28 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
CN111658647A (zh) * 2019-03-08 2020-09-15 首都医科大学宣武医院 沙利度胺及其衍生物的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders

Also Published As

Publication number Publication date
CA2563748A1 (en) 2005-11-03
EP1755599A4 (en) 2007-06-06
MXPA06012277A (es) 2007-01-31
IL178785A0 (en) 2007-05-15
AU2005234782A1 (en) 2005-11-03
CN1968696A (zh) 2007-05-23
ZA200609227B (en) 2008-06-25
US20050239719A1 (en) 2005-10-27
KR20070004123A (ko) 2007-01-05
WO2005102333A1 (en) 2005-11-03
EP1755599A1 (en) 2007-02-28
WO2005102333A9 (en) 2007-01-25
JP2007533759A (ja) 2007-11-22

Similar Documents

Publication Publication Date Title
BRPI0510166A (pt) método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
BRPI0510167A (pt) método para tratar, prevenir ou controlar hipertensão pulmonar
BRPI0510110A (pt) método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
BRPI0415971A (pt) método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
BR0316082A (pt) Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit
NO20064584L (no) Tetrahydropyridoindolderivater
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
BRPI0519030A2 (pt) mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica
BRPI0515103A (pt) composição farmacêutica, inalador, processos para preparar o mesmo, e uma composição farmacêutica, e, uso de uma composição farmacêutica
BRPI0518282A2 (pt) uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
BRPI0509400A (pt) métodos para tratar ou prevenir sono disfuncional, para controlar sono disfuncional e para melhorar o tempo para o começo do sono, a duração do sono ou a qualidade do sono ou realçar a capacidade para levantar sentindo-se renovado depois de um sono noturno, composição farmacêutica, e, kit adequado para o uso no tratamento, prevenção ou controle de sono disfuncional
BRPI0518054A (pt) composto ou um sal, estereoisÈmero ou derivado de n-óxido farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
BR112022019085A2 (pt) Uso de agentes para tratamento de condições respiratórias
BR0315593A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
NO20075400L (no) Fremgangsmater, sammensetninger og formuleringer for a forebygge eller lindre ugunstige virkninger i en pasient
BR112015030578A2 (pt) combinações farmacêuticas
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
BRPI0519621A2 (pt) usos de sabcomelina, de uma composiÇço farmacÊutica, de pelo menos um agente antimanÍaco ou estabilizador do humor, e de uma combinaÇço de sabcomelina ou um sal farmaceuticamente aceitÁvel da mesma e pelo menos um agente antimanÍaco ou estabilizador do humor, composiÇço farmacÊutica, kit de partes para uso no tratamento de distérbios bipolares, sabcomelina, e, mÉtodo de tratamento de distérbios biopolares
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
BRPI0518062A (pt) uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BR0315931A (pt) Método de tratar, prevenir ou controlar degeneração macular e composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.